• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Rezafungin is non-inferior to caspofungin in the treatment of candidemia and invasive candidiasis

byJessie WillisandTeddy Guo
January 25, 2023
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Global cure was achieved in 59% of the rezafungin group compared to 61% of the caspofungin group.

2. There were no significant differences in the 30-day all-cause mortality and rates of serious adverse events between the two groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Invasive candida infection is associated with high rates of mortality. Emerging resistance to current antifungals necessitates research in to novel treatments. This phase 3 non-inferiority trial evaluating rezafungin versus caspofungin in the treatment of patients with candidemia and invasive candidiasis. The primary outcome was global cure at day 14 and 30-day all-cause mortality. In result, rezafungin was shown to be non-inferior to caspofungin for both primary endpoints. In addition, rezafungin and caspofungin had similar trends of treatment-emergent adverse events and serious adverse events. Limitations of this study include the exclusion of other different forms of invasive candidiasis which could have responding differently to treatment. Nevertheless, this study provides high-quality evidence that supports further investigation of rezafungin as a treatment of candidemia and invasive candidiasis.

Click to read the study in The Lancet

Relevant Reading: Rezafungin: a novel antifungal for the treatment of invasive candidiasis

RELATED REPORTS

Esophageal candida infection associated with increased esophageal cancer risk in patients with achalasia

The Scan by 2 Minute Medicine®: Mammogram Recommendation Changes, COVID Called Off, Canadian Wildfires, and National Nurses Week

#VisualAbstract Sporotrichosis-associated cutaneous hypersensitivity reactions occur more frequently in the fixed cutaneous form

In-Depth [randomized controlled trial]: ReSTORE was a randomized non-inferiority phase 3 drug trial of intravenous rezafungin versus caspofungin in the treatment of patients candidaemia and invasive candidiasis. Eligible participants were aged 18 years or older, had mycological evidence of candidemia or invasive candidiasis, and were symptomatic. Exclusion criteria included those with prior treatment with more than two days of antifungal therapy, severe liver disease or transaminitis, or presence of an indwelling catheter. Participants were randomized 1:1 to rezafungin (n = 100) or caspofungin (n = 99). Treatment regimen in the rezafungin group was 400 mg rezafungin IV on day 1 and 200 mg IV on day 8 with optional third and fourth doses of 200 mg on day 15 and 22 if required. Treatment regimen in the caspofungin group was 70 mg IV on day 1 followed by 50 mg IV once daily for a minimum of 3 days and a maximum of 28 days. The primary endpoints were global cure at day 14 and 30-day all-cause mortality with an non-inferiority margin of 20% for both.

A total of 199 patients were randomized to either rezafungin (n = 100) or caspofungin (n = 99). The average age was 61 years and 81 (41%) were women. Global cure was achieved in 59% of the rezafungin group and 61% of the caspofungin group. A least one treatment-emergent adverse event was seen in 91% of the rezafungin group and 85% of the caspofungin group. 30-day all-cause mortality was 24% in the rezafungin group and 21% in the caspofungin group. Serious adverse events occurred in 56% of the rezafungin group and 53% of the caspofungin group. The most common treatment-emergent events were pyrexia, hypokalemia, pneumonia, septic shock, and anemia.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: candidaCandidiasiscaspofunginfungal infectionopportunistic infectionoral candidiasisrezafunginvaginal candidiasis
Previous Post

#VisualAbstract: Adjuvant capecitabine improves clinical outcomes in patients with locally advanced nasopharyngeal carcinoma

Next Post

Unvaccinated status increases risk of long COVID symptoms

RelatedReports

Hybrid minimally invasive esophagectomy associated with lower complication rates compared to open esophagectomy
Chronic Disease

Esophageal candida infection associated with increased esophageal cancer risk in patients with achalasia

January 24, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Mammogram Recommendation Changes, COVID Called Off, Canadian Wildfires, and National Nurses Week

May 18, 2023
#VisualAbstract Sporotrichosis-associated cutaneous hypersensitivity reactions occur more frequently in the fixed cutaneous form
StudyGraphics

#VisualAbstract Sporotrichosis-associated cutaneous hypersensitivity reactions occur more frequently in the fixed cutaneous form

August 5, 2021
Oral fluconazole in pregnancy associated with miscarriage
Obstetrics

Oral fluconazole in pregnancy associated with miscarriage

January 10, 2016
Next Post
Medical vaccine exemptions increase after elimination of nonmedical exemptions

Unvaccinated status increases risk of long COVID symptoms

#VisualAbstract: Telehealth treatment is effective in managing behavior problems in children with developmental delay

#VisualAbstract: Telehealth treatment is effective in managing behavior problems in children with developmental delay

Improved glycemic control in type 1 diabetics on very low-carbohydrate diets

Wellness Check: Nutrition

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.